{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood&page=31", "query": { "condition": "Blood", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 13516, "total_pages": 1352, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T02:25:02.379Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00000953", "title": "Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Chickenpox" ], "interventions": [ { "name": "Sorivudine", "type": "DRUG" }, { "name": "Acyclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-01", "last_synced_at": "2026-10-27T02:25:02.379Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Los Angeles, California • Martinez, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Martinez", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000953" }, { "nct_id": "NCT02531295", "title": "Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV", "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Euphorbia kansui extract powder prepared as tea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-05-15", "completion_date": "2020-03-19", "has_results": true, "last_update_posted_date": "2024-04-19", "last_synced_at": "2026-10-27T02:25:02.379Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02531295" }, { "nct_id": "NCT00000801", "title": "Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "HIV Infections" ], "interventions": [ { "name": "Filgrastim", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 33, "start_date": null, "completion_date": "1998-04", "has_results": false, "last_update_posted_date": "2012-11-01", "last_synced_at": "2026-10-27T02:25:02.379Z", "location_count": 7, "location_summary": "San Francisco, California • Denver, Colorado • Boston, Massachusetts + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Brookline", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000801" }, { "nct_id": "NCT05427812", "title": "Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "ISB 1442 SC injection escalating doses", "type": "DRUG" }, { "name": "ISB 1442 SC injection at RP2D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ichnos Sciences SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2022-09-27", "completion_date": "2024-11-19", "has_results": false, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-10-27T02:25:02.379Z", "location_count": 6, "location_summary": "Miami, Florida • Chicago, Illinois • Detroit, Michigan + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05427812" }, { "nct_id": "NCT06544265", "title": "SynKIR-310 for Relapsed/Refractory B-NHL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B Cell Lymphoma", "NHL, Adult", "Mantle Cell Lymphoma", "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Aggressive B-Cell Non-Hodgkin Lymphoma", "Indolent B-Cell Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "DLBCL - Diffuse Large B Cell Lymphoma", "HGBL With MYC and BCL2 and/or BCL6 Rearrangements", "High-grade B-cell Lymphoma", "Diffuse Large B Cell Lymphoma", "Large B-cell Lymphoma", "T-Cell/Histiocyte Rich Lymphoma", "Non-hodgkin Lymphoma,B Cell", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "Epstein-Barr Virus Positive DLBCL, Nos", "Follicular Lymphoma Grade 3B", "DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Follicular Lymphoma Grade 3", "Marginal Zone Splenic Lymphoma", "DLBCL", "Waldenstrom Macroglobulinemia", "Waldenstrom Macroglobulinaemia" ], "interventions": [ { "name": "SynKIR-310", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Verismo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2024-11-01", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-10-27T02:25:02.379Z", "location_count": 5, "location_summary": "Denver, Colorado • Atlanta, Georgia • Fairway, Kansas + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06544265" }, { "nct_id": "NCT01866267", "title": "Switching Undetectables to Selzentry", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Human Immunodeficiency Virus", "AIDS" ], "interventions": [ { "name": "Maraviroc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Hope Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 31, "start_date": "2013-01", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-11-19", "last_synced_at": "2026-10-27T02:25:02.379Z", "location_count": 1, "location_summary": "Bellaire, Texas", "locations": [ { "city": "Bellaire", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01866267" }, { "nct_id": "NCT03682536", "title": "A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Luspatercept", "type": "DRUG" }, { "name": "Epoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 363, "start_date": "2019-01-02", "completion_date": "2027-09-28", "has_results": true, "last_update_posted_date": "2024-11-20", "last_synced_at": "2026-10-27T02:25:02.379Z", "location_count": 25, "location_summary": "Berkeley, California • San Diego, California • Whittier, California + 22 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03682536" }, { "nct_id": "NCT00004171", "title": "Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": null, "start_date": "1999-10", "completion_date": "2002-06", "has_results": false, "last_update_posted_date": "2012-06-12", "last_synced_at": "2026-10-27T02:25:02.379Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004171" }, { "nct_id": "NCT00695071", "title": "Study to Assess Blood Levels of Itraconazole During a Two-Week Period", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stiefel, a GSK Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2008-06", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2011-09-26", "last_synced_at": "2026-10-27T02:25:02.379Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00695071" }, { "nct_id": "NCT00571844", "title": "ENCORE: Exercise and Nutritional Interventions for Cardiovascular Health", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "DASH diet", "type": "BEHAVIORAL" }, { "name": "DASH diet plus Weight loss", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 144, "start_date": "2003-10", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2014-07-14", "last_synced_at": "2026-10-27T02:25:02.379Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00571844" } ] }